Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

Myeloma Australia’s Medical and Scientific Advisory Group (MSAG)┬ápresents the article of the week.

Multiple myeloma (MM) is the third most common hematologic malignancy worldwide, characterized by excessive proliferation of monoclonal plasma cells. The development of novel anti-MM agents has expanded treatment options for MM patients and improved out-comes. Despite recent treatment advances, MM remains incurable, with most patients relapsing and developing treatment-refractory disease. Relapsed and refractory MM (RRMM) represents a challenging disease to treat, given the heterogeneity of the disease and patient population.

Importantly, advanced age, Eastern Cooperative Oncology Group performance status (ECOG PS), Inter- national Staging System (ISS), renal impairment, exposure to multiple lines of therapy, refractoriness to treatment, and the presence of high-risk cytogenetics have been associated with poor prognosis and shorter survival in patients with MM (including RRMM). Therefore,
there is a continued need to identify safe and efficacious and ultimately convenient treatments across the hetero- geneous RRMM patient population. For treatments with demonstrated safety and efficacy, convenience represents an important factor.

Read the full article here